BPC 157 10mg + TB500 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

This is a single co-formulated vial pairing two preclinical repair peptides in a 1:1 ratio: BPC-157 (a 15-amino-acid gastric peptide) 5 mg plus TB-500 (a Thymosin Beta-4 fragment) 5 mg — 10 mg total in one vial[1][3]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Neither peptide is FDA-approved — both are unapproved research chemicals, and the combination is not clinically validated (only a small, low-quality case series exists). Presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 10 mg blend vial → 3.33 mg/mL total (1.67 mg/mL of each peptide), a practical dilution for accurate dosing.
600–1000 mcg total blend once daily (300–500 mcg of each peptide), across an 8–12 week course.
At 3.33 mg/mL, 1 unit = 33.3 mcg total (16.67 mcg BPC + 16.67 mcg TB-500); 600 mcg = 18 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution of the combined vial, with accurate once-daily dosing, step by step

Advanced / Aggressive Approach (Acute-Injury Support)

Phase / Week(s)	Total Blend (1× daily)	Each Peptide	Volume (U-100 / mL)
Weeks 1–2	1000 mcg	500 mcg BPC + 500 mcg TB-500	30 units (0.30 mL)
Weeks 3–4	800 mcg	400 mcg BPC + 400 mcg TB-500	24 units (0.24 mL)
Weeks 5–8	600 mcg	300 mcg BPC + 300 mcg TB-500	18 units (0.18 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg blend vial → final concentration 3.33 mg/mL total (1.67 mg/mL of each peptide).
Typical daily range: 600–1000 mcg total blend once daily (300–500 mcg of each peptide), over an 8–12 week course. One draw delivers a 1:1 BPC:TB-500 split.
Easy measuring: At 3.33 mg/mL, 1 unit = 33.3 mcg total (16.67 mcg of each peptide) on a U-100 syringe. The 3.0 mL dilution keeps every dose at 18 units or more for accurate measuring.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day for 8–12 weeks (optionally extended to 16). Because the vial is co-formulated 1:1, every dose drawn delivers an equal split of BPC-157 and TB-500. These figures come from reference protocols, not from approved human dosing — the combination itself is not clinically validated.
For acute soft-tissue research scenarios, some protocols front-load a higher dose for the first four weeks before tapering to maintenance. Robust human dose-finding data do not exist for this blend; use with caution.
The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses[8] — it does not validate this subcutaneous blend. Treatment is generally limited to 8–12 weeks before cycling off to evaluate response.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution keeps each dose at 18 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with phased dosing (averaging ~700 mcg total blend per day across the cycle).

One 10 mg blend vial covers roughly two weeks at the averaged ~700 mcg/day, so plan about one vial every two weeks.
8 weeks: ~4 vials
12 weeks: ~6 vials
16 weeks: ~8 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 10 mg blend vial for reconstitution.
8 weeks (4 vials): ~12 mL → 2 bottles
16 weeks (8 vials): ~24 mL → 3 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Support soft-tissue repair via two complementary preclinical peptides — BPC-157 (cytoprotection, angiogenesis) and TB-500 (cell migration, angiogenesis); effects reported preclinically, not established in humans, and the combination is not clinically validated[5][6].
▪Schedule: Daily subcutaneous injections of the combined vial for 8–12 weeks, optionally extended to ~16 weeks.
▪Dose Range: 600–1000 mcg total blend per day (300–500 mcg of each peptide), delivered as a fixed 1:1 split.
▪Reconstitution: 3.0 mL bacteriostatic water per 10 mg blend vial gives 3.33 mg/mL total (1.67 mg/mL each) for accurate unit measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 600 mcg total once daily (300 mcg of each peptide) for Weeks 1–2.
▪Loading: Increase to 800 mcg total daily for Weeks 3–4 as tolerated.
▪Maintenance: Return to 600 mcg total daily for Weeks 5–8 and beyond.
▪Cycle Length: Typically 8–12 weeks; optional extension to ~16 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically. Each draw delivers a 1:1 BPC:TB-500 ratio.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: Both BPC-157 and TB-500 are prohibited by WADA for athletic use and are not FDA-approved for human administration; eligibility for compounding (regulatory status remains in flux through 2026) is not the same as approval[10].

How This Works

This is a single co-formulated vial holding two unrelated research peptides at a fixed 1:1 ratio — 5 mg of each, 10 mg total.

BPC-157 is a stable 15-amino-acid peptide derived from a human gastric protein. In preclinical models it has been associated with cytoprotection, modulation of nitric-oxide pathways and angiogenesis, with reported activity across gastrointestinal, musculoskeletal and other tissues[1][2].
TB-500 is a synthetic fragment of Thymosin Beta-4 whose core proposed action is the sequestering of G-actin to regulate actin polymerization — the process behind cell migration in wound healing — and which has been linked preclinically to angiogenesis and reduced inflammation[3][4].
The rationale for combining them is complementary mechanisms: BPC-157 for trophic and anti-inflammatory effects, TB-500 for cell migration and angiogenesis[8]. This rationale is theoretical.
Important caveat: the combination is not clinically validated. The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses — not this subcutaneous blend. Musculoskeletal “recovery” claims rest on animal data and anecdote and should be read as hypotheses.
Neither peptide is an approved medicine. Both are unapproved research chemicals presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What preclinical and veterinary literature describe; human evidence is limited and individual results vary.

▪Soft-tissue repair (preclinical): Animal studies of the individual peptides report faster wound healing via enhanced angiogenesis and cell migration[5][6].
▪Inflammation & cytoprotection (preclinical): BPC-157 shows gastroprotective and anti-inflammatory effects, and thymosin pathways are linked to reduced inflammation, in animal models[11].
▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions.
▪Note on humans: These benefits are not established in humans, and the BPC-157 + TB-500 combination is not clinically validated — no controlled trials of this blend have been completed[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
▪Sport restriction: Both BPC-157 and TB-500 are WADA-prohibited substances for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for the BPC-157 + TB-500 (5 mg + 5 mg) blend vial.

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for BPC 157 10mg + TB500 10mg.

BPC-157 + TB-500 (10mg Blend Vial) Dosage Protocol Open source
1 Journal of Physiology & Pharmacology BPC-157 (Body Protection Compound): pentadecapeptide from gastric juice with cytoprotective and wound-healing activity in preclinical models. View Source ↗ Open source
2 Journal of Chromatography A (PubMed) Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples. View Source ↗ Open source
3 WADA Scientific Research Investigation of TB-500 metabolism, synthesis of its metabolites, and detection limits. View Source ↗ Open source
4 Racing Medication & Testing Consortium Thymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine. View Source ↗ Open source
5 Journal of Investigative Dermatology (PubMed) Thymosin beta-4 accelerates wound healing in a preclinical model. View Source ↗ Open source
6 FASEB Journal (PubMed) Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 BPC-157 + TB-500 Case Series (PubMed) Small, low-quality case series of combined BPC-157 and TB-500 for joint injury at higher, intra-articular doses; not a controlled trial. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 WADA Prohibited List Classification of TB-500 as a prohibited substance in competitive sport. View Source ↗ Open source
11 Journal of Investigative Dermatology Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue. View Source ↗ Open source
12 Journal of Chromatography B (PubMed) Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis). View Source ↗ Open source
13 ClinicalTrials.gov Trial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides TB-500 (5 mg) product page — purity specifications and certificates of analysis. View Source ↗ Open source

Contents